Strategies for compliant content creation, MLR efficiency, and AI in Pharma.
The same one-pager is a ten-minute review or a lost weekend, depending entirely on how it arrived. What review readiness means, the eight-point pre-submission checklist, and where AI actually helps.
Read ArticleThese two get compared, and the comparison is usually wrong. What Veeva Vault PromoMats actually does, what PharmaText does, where the two genuinely overlap, and which one your situation calls for.
Read ArticleAn audit of 883 drug advertising claims retrieved every reference and graded it. Only 9% of the claims were precise, and 21% of the references did not support their claim. Why substantiation is decided at the wording, not at review.
Read ArticlePlenty of approved materials cite their sources but were never linked and anchored. How that referencing debt builds up, why it surfaces at renewal and reuse, and how to retrofit anchoring into an existing piece.
Read ArticleWhen someone asks AI about a rare disease, it returns one answer naming one set of sources. How to make it yours, why rare disease is the most winnable AI battleground, and the compliance moat behind it.
Read ArticleWhen a KOL speaks at a congress or webcast, anything you reuse still needs a reference, and spoken claims are uniquely hard to source. A practical workflow for referencing transcripts before MLR.
Read ArticleFour names, but not four styles. How AMA, Vancouver, ICMJE, and NLM citation formats actually relate, the one real difference that trips up medical writers, and which one to use.
Read ArticleA core-claims library is the highest-leverage way to speed up MLR review, and the one thing nobody wants to fund or maintain. What it is, why it works, why it rots, and what good looks like.
Read ArticleGeneral AI invents citations that look real, and in pharma a fake reference is exactly what MLR exists to catch. The failure modes, and a step-by-step workflow to verify every AI-generated citation.
Read ArticleWhen a launch multiplies your content volume, MLR becomes the bottleneck. The three ways to scale review, their trade-offs, and why the cheapest way to scale is to need less of it.
Read ArticleWho owns MLR review? The data on who does the work versus who is accountable, the cross-functional model most teams land on, and the practices that make shared ownership actually work.
Read ArticleLinking and anchoring is the manual task everyone hates, and the one that most decides how fast MLR review goes. What each means, where it breaks, and a checklist to get your reference pack review-ready.
Read ArticleThe five stages every promotional piece passes through, who signs off at each one, and the five reasons the cycle still loops. The version you finally upload to Veeva can be v35.
Read ArticleIn pharma promotional materials the burden is on you to prove every claim. Here is exactly what needs a reference, what does not, and why a citation alone is not enough.
Read ArticleWhat MLR review means in pharma, what MLR stands for, and how medical, legal and regulatory review differs from PRC and from European medical approval.
Read ArticleGlobal pharma spends $30B on content, yet 77% of it is never used. We analyze why the "more volume, more approval" model is broken and how to fix the 21-day MLR bottleneck.
Read ArticleIn late 2025, the FDA issued over 100 enforcement letters in a single week. We break down the top citations, from "CEO influencers" to missing risk info, and how to compliance-proof your drafts.
Read Article38% of pharma teams cite compliance as the top barrier to AI adoption. We explore why "Precision Traceability" is the only path forward.
Read ArticleMedical reviewers spend around 20% of their time acting as glorified spellcheckers. Here is how fixing the drafting phase saves the MLR cycle.
Read ArticleVeeva Vault is the system of record, but where does the work actually happen? It's time to fix the chaotic drafting phase.
Read Article